Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.

The Pfizer Bridge Program can support you in several ways
If your doctor has prescribed NGENLA, the Pfizer Bridge Program® can support you and your family through treatment.

The support includes a dedicated Patient Care Consultant (PCC) who will work directly with your doctor, insurance, and pharmacy to help you get started on NGENLA as soon as possible.

Provides eligible, commercially insured patients with copay program enrollment

Arranges for device training education with an experienced nurse

Assists with understanding the insurance process

Arranges for the first NGENLA shipment from the pharmacy and addresses issues that may lead to pharmacy delays or treatment interruptions

Click here to enroll in the NGENLA Copay Program.

Getting started with the Pfizer Bridge Program

1.  
Your doctor prescribes NGENLA

Your healthcare provider will send your child’s prescription to a specialty pharmacy of their choosing or one required by your insurance plan. They may also choose to enroll your child in the Pfizer Bridge Program.

2. Your doctor enrolls your child in the Pfizer Bridge Program

Once you've been prescribed NGENLA, your doctor will complete an enrollment form and fax it to the Pfizer Bridge Program. You'll need to sign some important consents to complete the Pfizer Bridge Program enrollment process.

Note: If you signed these forms in your healthcare provider’s office, no action needed

Complete your enrollment

3.    
Work with our Pfizer 
Bridge Program Team

Once enrolled, you'll receive a call within 1 business day to welcome you into the program. This call will come from 1-800-645-1280, so be sure to save this number as the Pfizer Bridge Program in your contacts. We can help you understand your insurance coverage, navigate prior-authorization processes, 
and get connected with the appropriate specialty pharmacy, device training, and other support resources.

Complete your enrollment

Let's get started! The Pfizer Bridge Program is here to support your treatment journey with NGENLA. Here are some key steps you can expect:Prescribed NGENLA

Once you and your child's doctor determine that NGENLA is the right treatment, the doctor will prescribe the therapy.

 Pfizer Bridge Program Enrollment Form

You and your child's doctor will then complete the Pfizer Bridge Program Enrollment Form. A PCC, who is part of the Pfizer Bridge Program, will contact you following your enrollment. Watch for a call from 1-800-645-1280.

 Benefits Verification

Your child's doctor or the PCC will contact your insurance plan to confirm the growth hormone products available to your child and review the information with you.

 Prior Authorization Submission

Prescription drug plans (“plan”) often require your child's doctor to get approval or prior authorization before your child can be treated with NGENLA.

 Insurance Decision

Your plan will review the information submitted by your child's doctor and either approve or deny your child's prescription. Your child's doctor or the PCC will contact you with the plan’s decision. If your child's prescription is denied, the Pfizer Bridge Program can provide information on appeals requirements.

 Receive NGENLA

A specialty pharmacy will send NGENLA directly to your home. Your PCC can share the specialty pharmacy information with you, assist with coordinating medication shipments, and help with any medication or device issues that may arise.

 Device Training and Education

The Pfizer Bridge Program can help arrange in-home or virtual device training by an experienced nurse. View demonstration videos here. You can also contact the device support hotline at 1-800-645-1280 to speak with an experienced professional.

 Reauthorization

Plans may require your child to be reapproved to continue growth hormone treatment. Your PCC will contact you to ensure there is no lapse in your child's NGENLA treatment. 
Be sure to attend all scheduled doctor's appointments to prevent any delays in reauthorization.
For more information,
call 1-800-645-1280,
M-F 9-7 ET

Important Safety Information & Use

Important Safety
Information & Use

INDICATION
NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.
IMPORTANT SAFETY INFORMATION
Do not use NGENLA if:
  • your child has a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems.
  • your child is allergic to somatrogon-ghla or any of the ingredients in NGENLA.
  • your child has closed bone growth plates.
  • your child has cancer or other tumors.
  • your child’s healthcare provider tells you that your child has certain types of eye problems caused by diabetes.
  • your child has Prader-Willi syndrome, is severely obese, or has breathing problems including sleep apnea (briefly stopping breathing during sleep).
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
  • has had heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • has had a history of problems breathing while they slept.
  • has or has had cancer or any tumor.
  • has diabetes.
  • is pregnant or plans to become pregnant. It is not known if NGENLA will harm your child’s unborn baby. Talk to your child’s healthcare provider if your child is pregnant or plans to become pregnant.
  • is breastfeeding or plans to breastfeed. It is not known if NGENLA passes into breast milk. You and your child’s healthcare provider should decide if they will take NGENLA while breastfeeding.
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works.

NGENLA may cause serious side effects, including:
  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • serious allergic reactions. Get medical help right away if your child has the following symptoms: swelling of the face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in the chest, sweating.
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your child’s healthcare provider will need to monitor your child for a return of cancer or a tumor. Contact your child’s healthcare provider if your child starts to have headaches, or has changes in behavior, changes in vision, or changes in moles, birthmarks, or the color of the skin.
  • new or worsening high blood sugar or diabetes. Your child’s blood sugar may need to be monitored during treatment with NGENLA.
  • increase in pressure inside the skull. If your child has headaches, eye problems, nausea or vomiting, contact your child’s healthcare provider.
  • your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in the joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Fluid retention can happen in children during treatment with NGENLA. Tell your child’s healthcare provider if your child has any of these signs or symptoms of fluid retention.
  • decrease in a hormone called cortisol. Your child’s healthcare provider will do blood tests to check your child’s cortisol levels. Tell your child’s healthcare provider if your child has severe fatigue, dizziness, weakness, vomiting, dehydration, or weight loss.
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well NGENLA works. Your child’s healthcare provider will do blood tests to check your child’s hormone levels.
  • hip and knee pain or limp (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
  • worsening of curvature of the spine (scoliosis). If your child has scoliosis, your child will need to be checked often for an increase in the curve of the spine.
  • severe and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s healthcare provider if your child has any new abdominal pain.
  • loss of fat and tissue weakness in the area of skin you inject. Talk to your child’s healthcare provider about rotating the areas where you inject NGENLA.
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea.
  • increase in phosphorus, alkaline phosphatase and parathyroid hormone levels in the blood. Your child’s healthcare provider will do blood tests to check this.
The most common side effects (≥5%) of NGENLA include: injection site reactions (such as pain, swelling, rash, itching, bleeding), common cold, headache, fever, low red blood cells (anemia), cough, vomiting, decrease in thyroid hormone levels, stomach (abdominal) pain, rash, throat pain.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0599